MedTrace Logo

Effect of Docosa-Hexanoic Acid (DHA) Supplements During Pregnancy on Newborn Outcomes in India.

NCT01580345 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2017-02-23

No results posted yet for this study

Summary

The 'DHANI randomized controlled trial" seeks to examine the effects of prenatal DHA supplementation on newborn anthropometry where in healthy pregnant will be assigned to receive either 400 mg of DHA or a placebo daily from ≤20 weeks gestation through delivery.

Conditions

  • Pregnancy

Interventions

DIETARY_SUPPLEMENT

Docosa-hexaenoic acid (DHA)

400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.

DIETARY_SUPPLEMENT

Placebo

400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.

Sponsors & Collaborators

  • Department of Science and Technology, Government of India

    collaborator UNKNOWN

  • Jawaharlal Nehru Medical College

    collaborator OTHER

  • Centre for Chronic Disease Control, India

    lead OTHER

Principal Investigators

  • Shweta Khandelwal, PhD · Centre for Chronic Disease Control (CCDC)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-12-06
Completion
2016-12-09

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01580345 on ClinicalTrials.gov